Sino Biopharmaceutical (HK:1177) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical has announced that its Eribulin Mesilate Injection has been approved by China’s National Medical Products Administration for treating advanced breast cancer. This approval marks one of the first three such injections sanctioned in China, highlighting the company’s strong R&D capabilities. With several promising drugs in the pipeline, Sino Biopharmaceutical is positioning itself as a leader in breast cancer treatment innovation.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.